OakChart

Veracyte Inc

VCYTHealthcare·Diagnostics & Research·USA·Mid·NASD·Nov 11 • 3:59 PM ET

25.11+1.05 (4.36%)
2026-11-11 22:03 CET
Market cap
1,941.53 USD m
Revenue, TTM
581.78 USD m
Net income, TTM
126.85 USD m
Free cash flow, TTM
161.95 USD m
EPS diluted, TTM
1.55
P/E
16.20
Compare

Price

VCYT against its 20, 50 and 200-day averages
2050200beat
20.0030.0040.0050.0060.007.5M15.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VCYTclose 25.1120-day 42.1250-day 42.98200-day 42.5325.1152w high52w low

58.8% under the 52-week high of 60.91 on 30 Jun 2026. 52-week low 21.91 on 5 Nov 2026. Last 15 sessions, 140.8% high to low

Volume 1.95× normal · the line is the 50-bar volume average

Profile

VCYT
52-week range, 8% of the way up
21.9160.91

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

IndexRUT
Employees755
IPOOct 30, 2013
Beta2.03
ATR, 14d3.90
Rel volume1.95
Short float12.07%
Insider own1.83%
Inst own116.29%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.03B
Enterprise Value1.70B
Income126.85M
Sales581.78M
Book/sh17.77
Cash/sh4.59
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees755
IPOOct 30, 2013

Ratios

P/E16.20
Forward P/E15.59
PEG-
P/S3.48
P/B1.41
P/C5.47
P/FCF12.51
EV/EBITDA15.18
EV/Sales2.92
Quick Ratio5.25
Current Ratio5.56
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)1.55
EPS next Y1.61
EPS next Q0.39
EPS this Y7.79%
EPS next Y-16.07%
EPS next 5Y-1.06%
EPS past 3/5Y- -
Sales past 3/5Y20.37% 34.50%
EPS Y/Y TTM311.25%
Sales Y/Y TTM17.50%
EPS Q/Q58.48%
Sales Q/Q15.08%
EarningsNov 04 AMC
EPS/Sales Surpr.24.33% 3.14%

Ownership

Insider Own1.83%
Insider Trans-14.93%
Inst Own116.29%
Inst Trans2.97%
ROA8.63%
ROE9.43%
ROIC8.65%
Gross Margin71.63%
Oper. Margin15.51%
Profit Margin21.80%
SMA20-40.38%
SMA50-41.57%
SMA200-40.95%
Trades-

Technical

Shs Outstand80.66M
Shs Float79.22M
Short Float12.07%
Short Ratio5.57
Short Interest9.56M
52W High60.91 -58.78%
52W Low21.91 14.61%
Volatility14.68% 7.14%
ATR (14)3.90
RSI (14)28.71
Beta2.03
Rel Volume1.95
Avg Volume1.72M
Volume3,338,797

Performance

Perf Week-52.19%
Perf Month-41.75%
Perf Quarter-41.06%
Perf Half Y-34.35%
Perf YTD-40.36%
Perf Year-41.14%
Perf 3Y13.11%
Perf 5Y-46.57%
Perf 10Y258.71%
Recom1.46
Target Price47.20
Prev Close24.06
Price25.11
Change %4.36%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 05, 2026DowngradeLLeerink PartnersOutperform → Market Perform$35+39.4%
Jul 15, 2026InitiatedPPiper SandlerOverweight$66+162.8%
Jun 02, 2026ResumedWWolfe ResearchOutperform$55+119.0%
Apr 13, 2026InitiatedJJefferiesBuy$45+79.2%
Dec 02, 2025ResumedMMorgan StanleyUnderweight$48+91.2%
Oct 20, 2025InitiatedCCanaccord GenuityHold$40+59.3%
Mar 20, 2025InitiatedCCraig HallumBuy$45+79.2%
Dec 05, 2024DowngradeGGoldmanBuy → Neutral$38 → $37+47.4%
Nov 15, 2024InitiatedWWolfe ResearchOutperform$50+99.1%
Oct 16, 2024InitiatedUUBSBuy$43+71.2%

Peers

Mkt cap
TickerCompanyMkt cap
MYGNMyriad Genetics Inc548.68M
NEONeogenomics Inc2.18B
CSTLCastle Biosciences Inc1.05B
GHGuardant Health Inc20.94B
MDXHMDxHealth SA13.98M
BDSXBiodesix Inc112.22M
DGXQuest Diagnostics Inc28.46B
NTRANatera Inc46.38B
GRALGRAIL Inc5.65B
TEMTempus AI Inc14.49B

Insider trading

latest 14 of 67
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Holstein JensDirectorSep 24 '26Option Exercise35.307,500264,75034,971Oct 28 04:05 PM
Holstein JensDirectorOct 27 '26Option Exercise35.307,500264,75034,971Oct 28 04:05 PM
Holstein JensDirectorOct 27 '26Sale50.007,500375,00027,471Oct 28 04:05 PM
Holstein JensDirectorSep 24 '26Sale47.007,500352,50027,471Oct 28 04:05 PM
EASTHAM KARINDirectorOct 27 '26Option Exercise27.0110,000270,10025,097Oct 28 04:05 PM
EASTHAM KARINDirectorOct 27 '26Sale50.0014,850742,57310,247Oct 28 04:05 PM
KARIN EASTHAMDirectorOct 27 '26Proposed Sale48.2014,850715,770Oct 27 04:30 PM
JENS HOLSTEINDirectorOct 27 '26Proposed Sale50.007,500375,000Oct 27 04:06 PM
Bhanji MunaDirectorOct 19 '26Sale43.701,86481,45740,854Oct 20 04:10 PM
JENS HOLSTEINDirectorSep 24 '26Proposed Sale47.007,500352,500Sep 24 04:25 PM
Leite JohnGlobal Chief Commercial OffSep 21 '26Sale40.004,015160,600124,329Sep 22 05:16 PM
JOHN LEITEOfficerSep 21 '26Proposed Sale39.804,015159,777Sep 21 04:31 PM
Holstein JensDirectorSep 14 '26Sale40.955,000204,74727,471Sep 16 04:08 PM
JENS HOLSTEINDirectorSep 14 '26Proposed Sale40.955,000204,747Sep 14 05:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.03B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
ARKEARK DIET Q3 Buffer ETFAUM: 1.45M
ARKKARK Innovation ETFAUM: 5.97B
ARKGARK Genomic Revolution ETFAUM: 1.97B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-040.5100.4100.380151.75147.1311
2026Q22026-07-300.5400.4100.311150.32144.5912
2026Q12026-05-050.5200.3340.353139.07130.3611
2025Q42026-02-250.5300.4090.506140.64135.4312
2025Q32025-11-040.5100.3210.240131.87124.9712
2025Q22025-08-060.4400.279-0.013130.2121.049
2025Q12025-05-070.3100.1230.088114.5111.277
2024Q42025-02-240.0600.1130.064118.63116.76
2024Q32024-11-060.1900.0320.193115.86109.828
2024Q22024-08-060.070-0.0160.074114.4100.278
2024Q12024-05-07-0.020-0.159-0.02596.8493.357
2023Q42024-02-22-0.390-0.100-0.38798.2091.975
2023Q32023-11-07-0.410-0.147-0.40790.1184.368
2023Q22023-08-08-0.120-0.152-0.11690.3283.058
2023Q12023-05-04-0.110-0.135-0.11282.4275.808
2022Q42023-02-22-0.050-0.151-0.05480.3073.947

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.270-0.200-0.273120.37120.22
2020FY-0.660-0.614-0.656117.48115.33
2021FY-1.110-1.137-1.113219.51214.82
2022FY-0.510-0.608-0.511296.54291.31
2023FY-1.020-0.712-1.024361.05354.58
2024FY0.3100.3600.309445.76443.91
2025FY1.7801.6630.820517.15511.67
2026FY-1.919--591.55
2027FY-1.610--639.14
2028FY-1.724--692.18
2029FY-2.070--837.31
2030FY-2.175--928.61

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-091208152.04148.3159.9
2026Q4S2026-11-061207152.61148.3159.9
2026Q4S2026-11-051205154.22148.8159.9
2026Q4S2026-11-041200157.29154.7159.9
2026Q4S2026-10-161200157.29154.7159.9
2026Q4S2026-10-151200157.29154.7159.9
2026Q4S2026-10-141200157.28154.7159.9
2026Q4S2026-09-301270157.28154.7159.9
2026Q4S2026-09-221270157.32155.2159.9
2026Q4S2026-09-141270157.33155.2159.9
2026Q4S2026-09-081270157.33155.2160
2026Q4S2026-07-311170157.29155.2160
2026Q4S2026-07-301100154.96153.3157.23
2026Q4S2026-07-201100154.96153.3157.23

Estimate history

EPS, annual-0.914-0.621-0.273-0.656-1.113-0.511-1.0240.3090.8241.5498
Period201720182019202020212022202320242025TTM
EPS, quarterly0.1930.0640.088-0.0130.240.5060.3530.3110.381
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual71.95392.008120.368117.483219.514296.536361.051445.764517.145581.78
Period201720182019202020212022202320242025TTM
Sales, quarterly115.86118.632114.473130.164131.872140.636139.071150.321151.754
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual34.2140.86349.62558.20171.12371.95973.26577.77379.35980.656
Period201720182019202020212022202320242025MRQ
Shares, quarterly77.49177.77378.30678.59979.03479.35979.79280.36480.656
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue581.78517.14445.76361.05296.54219.51117.48120.3792.01
Cost of Goods Sold Incl. D&A165.04162.52156.22137.90125.7092.5447.2439.6236.20
Gross Profit416.74354.62289.55223.15170.83126.9770.2580.7555.81
Selling, General and Administrative Excl. Other326.51261.05256.33235.22208.44185.96102.0495.8878.04
Research and Development109.5569.1768.0256.3740.0829.5316.9614.5614.42
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income90.2393.5833.21-12.06-37.61-58.99-31.80-15.13-22.23
Interest Expense0.000.000.000.010.200.240.230.681.96
Unusual Expense-14.4334.1017.0773.733.4722.913.59--
Net Income Before Taxes118.2568.2025.74-76.61-36.43-81.65-34.91-12.60-23.00
Income Taxes-8.601.851.61-2.210.13-6.090.000.000.00
Consolidated Net Income126.8566.3524.14-74.40-36.56-75.56-34.91-12.60-23.00
Net Income From Continuing Operations126.8566.3524.14-74.40-36.56-75.56-34.91-12.60-23.00
Net Income126.8566.3524.14-74.40-36.56-75.56-34.91-12.60-23.00
EPS (Recurring)1.411.120.46-0.31-0.48-0.88-0.61-0.27-0.62
EPS (Basic, Before Extraordinaries)1.590.840.32-1.02-0.51-1.11-0.66-0.27-0.62
EPS (Diluted)1.550.820.31-1.02-0.51-1.11-0.66-0.27-0.62
EBITDA111.78114.9956.6715.12-8.36-37.77-22.89-11.01-18.31
Non-Operating Income (Expense)13.588.729.609.204.850.490.713.211.20
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense40.8534.4428.6426.1821.1116.3912.999.815.96
Price To Earnings Ratio15.5215.52-------
Price To Sales Ratio6.556.566.945.545.7312.7422.1810.705.06
Gross Margin71.6368.5764.9561.8157.6157.8459.7967.0960.66
Operating Margin15.5118.097.45-3.34-12.68-26.87-27.06-12.57-24.16
Net Margin21.8012.835.41-20.61-12.33-34.42-29.71-10.47-25.00
Shares Outstanding80.6679.3677.7773.2671.9671.1258.2049.6340.86
Market Capitalization1,941.531,941.533,068.982,009.321,702.702,926.982,833.491,363.61509.98

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue151.75150.32139.07140.64131.87130.16114.47118.63
Cost of Goods Sold Incl. D&A45.0742.1938.4939.2842.5242.4137.0742.16
Gross Profit106.68108.13100.58101.3589.3687.7577.4076.48
Selling, General and Administrative Excl. Other90.1184.2576.7375.4166.2473.4476.4565.42
Research and Development32.1629.4427.1020.8515.5415.8317.2918.83
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income16.5723.8823.8525.9423.1114.310.9511.05
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.400.60-3.38-11.260.1718.58-1.956.88
Net Income Before Taxes21.1226.5229.9740.6318.891.257.433.44
Income Taxes-10.381.031.27-0.52-0.252.230.38-1.67
Consolidated Net Income31.5025.4928.7141.1519.14-0.987.055.11
Net Income From Continuing Operations31.5025.4928.7141.1519.14-0.987.055.11
Net Income31.5025.4928.7141.1519.14-0.987.055.11
EPS (Recurring)0.380.320.320.410.240.150.070.12
EPS (Basic, Before Extraordinaries)0.390.320.360.520.24-0.010.090.07
EPS (Diluted)0.380.310.350.510.24-0.010.090.06
EBITDA22.5528.7229.2831.2428.3819.806.3117.31
Non-Operating Income (Expense)4.153.242.753.44-4.065.524.52-0.73
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.0311.1310.088.618.508.688.667.61
Price To Earnings Ratio15.5254.0639.22110.88103.1964.4396.74-
Price To Sales Ratio6.558.584.836.635.534.425.127.10
Gross Margin70.3071.9372.3272.0767.7667.4267.6164.47
Operating Margin10.9215.8917.1518.4417.5311.000.839.32
Net Margin20.7616.9620.6429.2614.51-0.756.164.31
Shares Outstanding80.6680.3679.7979.3679.0378.6078.3177.77
Market Capitalization1,941.534,686.222,559.363,327.972,700.802,116.842,311.063,068.98

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments412.89289.44216.45178.85173.20349.36159.3278.0033.89
Short Term Receivables44.6650.8345.0844.0241.4618.4619.3313.1712.72
Inventories20.5521.7516.1314.2911.224.666.813.405.32
Other Current Assets10.2810.257.9611.4717.223.202.232.392.00
Total Current Assets488.38372.27285.62248.64243.10375.68187.6996.9553.93
Net Property, Plant & Equipment58.7971.1430.8630.8631.1416.8317.748.949.69
Total Investments and Advances1.651.540.880.750.750.600.600.600.60
Intangible Assets856.30848.10791.58870.76910.6362.6567.7413.0614.12
Deferred Tax Assets31.2033.9822.9132.2237.26----
Other Assets0.906.985.975.422.201.401.441.090.33
Total Assets1,437.211,334.021,137.821,188.641,225.09457.16275.21120.6478.67
Short Term Debt Incl. Current Port. of LT Debt4.057.505.114.074.761.591.411.360.00
Accounts Payable4.598.6312.9411.9112.363.122.332.523.85
Other Current Liabilities51.2962.5043.1946.6347.0312.0813.739.198.18
Total Current Liabilities59.9478.6361.2462.6164.1516.7817.4713.0612.03
Long Term Debt35.6043.247.5310.6514.1010.7312.2023.9325.25
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities31.8435.2123.6536.7542.85----
Other Liabilities0.260.971.303.437.478.426.093.904.17
Total Liabilities127.64158.0593.72113.44128.5735.9335.7640.8841.44
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,309.581,175.971,044.101,075.201,096.51421.23239.4679.7537.23
Total Shareholders Equity1,309.581,175.971,044.101,075.201,096.51421.23239.4679.7537.23
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,309.581,175.971,044.101,075.201,096.51421.23239.4679.7537.23
Total Liabilities & Stockholders Equity1,437.211,334.021,137.821,188.641,225.09457.16275.21120.6478.67
Book Value Per Share16.5015.1214.2514.9415.427.244.831.951.09
Tangible Book Value Per Share5.714.223.452.842.616.163.461.630.68
Full-Time Employees755824815787761320354270246
Price to Book Ratio1.352.611.911.622.676.765.796.455.18
Return on Assets4.791.95-6.40-3.03-8.98-9.53-6.37-23.08-34.50
Return on Equity5.342.17-7.02-3.37-9.96-10.57-7.89-39.32-64.05
Return on Invested Capital4.931.98-7.08-3.37-6.80-8.08-5.01-22.18-49.63
Quick Ratio7.814.464.403.743.6122.1110.357.164.04
Current Ratio8.154.734.663.973.7922.3910.747.424.48

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income126.8566.3524.14-74.40-36.56-75.56-34.91-12.60-23.00
Depreciation21.5521.4123.4627.1929.2521.238.914.123.92
Other Funds (Non Cash)40.9751.4249.0599.4431.0924.7616.7710.106.21
Funds from Operations177.20138.6196.4248.3823.92-35.84-9.231.61-12.87
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-3.32-2.30-21.32-4.16-16.384.22-0.48-4.85-0.65
Cash from Operating Activities173.88136.3175.1044.227.54-31.62-9.71-3.23-13.52
Capital Expenditures-11.94-9.68-11.29-9.96-8.55-5.38-2.84-2.76-1.87
Net Assets From Acquisitions-153.190.005.010.000.00-736.830.00-40.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.020.00
Purchase or Sale of Investments-116.823.31-50.0025.07-20.843.00-1.000.000.00
Purchase of Investments-285.00-150.00-50.00-19.70-33.520.00-1.000.000.00
Sale Or Maturity of Investments168.18153.310.0044.7712.683.000.000.000.00
Other Uses-4.47-2.850.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-286.41-9.21-56.2715.11-29.39-739.21-3.84-42.73-1.87
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock18.0014.0819.999.587.94605.35207.54152.5059.39
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock18.0014.0819.999.587.94605.35207.54152.5059.39
Proceedsfrom Stock Options0.000.000.000.000.00593.82193.83137.8555.04
Issuance or Reduction of Debt, Net0.000.000.000.00-1.280.00-0.10-25.21-0.29
Change in Long Term Debt0.000.000.000.00-1.280.00-0.10-25.21-0.29
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00-1.280.00-0.10-25.21-0.29
Net Financing Active Other Cash Flow-21.12-18.30-15.09-6.74-3.17-9.03-3.850.000.40
Other Financing Activities Uses-21.12-18.30-15.09-6.74-3.17-9.03-3.850.000.00
Cash from Financing Activities-3.12-4.224.902.843.49596.32203.59127.2959.50
Exchange Rate Effect-0.090.72-0.420.16-0.59-1.51---
Net Change in Cash-115.74123.5923.3062.33-18.95-176.02190.0581.3244.10
Free Cash Flow161.95126.6363.8134.26-1.01-37.00-12.55-5.99-15.39
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow23.5326.7948.5158.33-----
Deferred Taxes & Investment Tax Credit--0.58-0.23-3.840.13-6.260.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments370.53485.23439.06412.89366.43320.72
Short Term Receivables56.7954.1850.1144.6647.8350.81
Inventories25.8222.6621.4220.5520.3325.02
Other Current Assets14.7412.7111.5910.2814.6418.13
Total Current Assets467.88574.77522.17488.38449.22414.68
Net Property, Plant & Equipment59.9757.1058.5258.7956.2057.23
Total Investments and Advances1.651.671.661.651.641.65
Intangible Assets1,040.46849.85853.02856.30859.63869.06
Deferred Tax Assets---31.20--
Other Assets3.312.981.030.901.091.48
Total Assets1,573.261,486.371,436.401,437.211,367.791,344.10
Short Term Debt Incl. Current Port. of LT Debt6.815.784.354.054.286.41
Accounts Payable9.718.026.914.595.5111.45
Other Current Liabilities67.6948.9444.8651.2962.3658.57
Total Current Liabilities84.2162.7456.1259.9472.1576.43
Long Term Debt33.9234.3334.9935.6036.1744.23
Provision for Risks Charges0.000.000.000.000.000.50
Deferred Tax Liabilities1.620.640.6431.841.211.30
Other Liabilities20.250.260.260.260.580.58
Total Liabilities139.9997.9691.99127.64110.12123.05
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,433.261,388.401,344.411,309.581,257.671,221.06
Total Shareholders Equity1,433.261,388.401,344.411,309.581,257.671,221.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,433.261,388.401,344.411,309.581,257.671,221.06
Total Liabilities & Stockholders Equity1,573.261,486.371,436.401,437.211,367.791,344.10
Book Value Per Share17.7717.2816.8516.5015.9115.54
Tangible Book Value Per Share4.876.706.165.715.044.48
Full-Time Employees---755--
Price to Book Ratio1.353.491.952.652.211.77
Return on Assets8.638.096.404.792.292.04
Return on Equity9.438.776.935.342.492.24
Return on Invested Capital2.151.792.083.061.48-0.08
Quick Ratio5.258.808.927.815.945.10
Current Ratio5.569.169.318.156.235.43

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income31.5025.4928.7141.1519.14-0.98
Depreciation5.984.845.435.305.275.49
Other Funds (Non Cash)13.1713.7612.811.2314.0627.81
Funds from Operations39.0644.0946.9447.1038.3832.38
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.191.74-11.735.486.381.23
Cash from Operating Activities40.2645.8335.2252.5844.7633.60
Capital Expenditures-2.33-2.86-2.96-3.78-2.79-1.29
Net Assets From Acquisitions-153.190.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments16.05-9.06-125.001.2051.051.06
Purchase of Investments-50.00-60.00-125.00-50.000.00-50.00
Sale Or Maturity of Investments66.0550.940.0051.2051.0551.06
Other Uses0.00-1.620.00-2.850.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-139.47-13.54-127.96-5.4348.26-0.22
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.338.432.733.515.791.81
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.338.432.733.515.791.81
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-3.80-4.29-9.36-3.66-2.81-2.38
Other Financing Activities Uses-3.80-4.29-9.36-3.66-2.81-2.38
Cash from Financing Activities-0.484.14-6.63-0.152.98-0.57
Exchange Rate Effect-0.02-0.03-0.060.010.060.57
Net Change in Cash-99.7136.39-99.4347.0296.0633.39
Free Cash Flow37.9242.9732.2548.8041.9732.32
Price to Free Cash Flow23.5329.0316.8627.0627.8625.24

Revenue breakdown

Biopharmaceutical And Other2024: 13.15M 2025: 9.66M
Product2024: 13.65M 2025: 14.33M
Testing2024: 418.96M 2025: 493.15M
Non-US2024: 22.23M 2025: 20.55M
United States2024: 423.54M 2025: 496.60M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.07%9.6M79.2M1.38M
2026-10-1512.44%9.8M78.9M1.36M
2026-09-3012.90%10.2M78.9M1.33M
2026-09-1510.65%8.4M78.9M1.33M
2026-08-3110.24%8.1M78.9M1.37M
2026-08-148.61%6.8M78.9M1.32M
2026-07-318.77%6.9M78.2M1.32M
2026-07-158.60%6.7M77.6M1.20M
2026-06-308.65%6.7M77.6M1.14M
2026-06-1510.94%8.5M77.6M1.04M
2026-05-299.47%7.4M77.7M982.47K
2026-05-1511.05%8.6M77.7M945.16K
2026-04-308.82%6.9M77.9M897.43K
2026-04-158.32%6.5M77.6M911.71K
2026-03-318.14%6.3M77.7M929.87K
2026-03-136.92%5.4M77.7M827.65K
2026-02-277.06%5.5M77.7M812.24K
2026-02-137.82%6.1M77.3M853.78K
2026-01-307.28%5.6M77.3M913.62K
2026-01-156.69%5.2M77.3M890.71K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5010.6014.800.005.9780.000.000.963-0.0530.003
call15.008.1012.400.004.9100.000.000.953-0.0510.004
call17.505.709.900.003.9190.000.000.938-0.0480.005
call20.003.407.105.412.8732.000.000.913-0.0430.006
call22.502.403.602.801.36942.004.000.788-0.0650.011
call25.000.501.350.850.8251200.000.562-0.1530.015
call30.000.000.200.100.73089523.000.080-0.0240.006
call35.000.000.300.671.50334.000.000.082-0.0460.006
call40.000.003.400.051.57417.000.000.043-0.0320.004
call45.000.001.600.102.19218.000.000.061-0.0580.005
call50.000.000.050.031.9972810.000.019-0.0190.002
call55.000.000.050.082.2077570.000.018-0.0190.002
call60.000.003.400.052.37934.000.000.017-0.0220.002
call65.000.003.400.002.5950.000.000.016-0.0220.002
call70.000.003.400.002.7580.000.000.015-0.0230.001
put12.500.003.400.002.8840.000.00-0.037-0.0520.003
put15.000.003.400.002.6340.000.00-0.073-0.0800.005
put17.500.003.400.001.6690.000.00-0.063-0.0460.005
put20.000.050.200.151.45748.000.00-0.126-0.0660.008
put22.500.000.500.250.98527810.00-0.212-0.0620.011
put25.000.003.901.102.60811.000.00-0.429-0.1550.015
put30.003.006.504.962.20028.000.00-0.876-0.0370.008
put35.008.0011.5012.002.8294970.00-0.915-0.0450.006
put40.0013.0016.5015.603.4865010.00-0.930-0.0500.005
put45.0017.8021.8019.954.0354911.00-0.939-0.0540.005
put50.0022.8026.8026.284.4550.000.00-0.981-0.0150.002
put55.0027.7032.006.984.9790.000.00-0.982-0.0150.002
put60.0032.7037.000.005.2800.000.00-0.983-0.0150.002
put65.0037.7042.000.005.5500.000.00-0.984-0.0150.002
put70.0042.7047.000.005.8340.000.00-0.985-0.0150.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-05SCHEDULE 13G/ASEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-294Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-27144Filing for proposed sale of securities under Rule 144.SEC
2026-10-27144Filing for proposed sale of securities under Rule 144.SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-09-24144Filing for proposed sale of securities under Rule 144.SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-148-KCurrent report2026-09-10SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-3110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-18144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001.20M3
2026-09001.66M7
2026-080000
2026-070000
2026-06008.15M5
2026-05001.93M3
2026-040000
2026-03003.21M5
2026-020000
2026-010000
2025-12002.48M6
2025-11003.95M9

Institutional holders

Manager% owned
BlackRock, Inc.16.90%
FMR LLC8.10%
Artisan Partners Limited Partnership6.94%
VANGUARD PORTFOLIO MANAGEMENT LLC5.91%
STATE STREET CORP5.89%
VANGUARD CAPITAL MANAGEMENT LLC4.50%
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC3.37%
DIMENSIONAL FUND ADVISORS LP3.35%
FIRST TRUST ADVISORS LP3.14%
GW&K Investment Management, LLC3.00%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF6.02%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.17%
First Trust NYSE Arca Biotechnology Index Fund3.06%
iShares Russell 2000 ETF2.61%
VANGUARD SMALL-CAP INDEX FUND2.29%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.88%
Artisan Mid Cap Fund1.55%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.32%
ARK Innovation ETF1.29%
Select Health Care Portfolio1.24%

OakChart. VCYT. Cached 15 minutes.